Saturday, April 13 2019 - Tuesday, April 16 2019

Amsterdam, The Netherlands

VenatoRx Pharmaceuticals will have 12 poster presentations at ECCMID 2019 featuring its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, respectively.

American Chemical Society National Meeting 2019
Sunday, March 31 2019 - Thursday, April 04 2019

Orlando, FL

President and CEO, Christopher J. Burns, Ph.D., will present the Company's novel, orally-bioavailable beta-lactamase inhibitor, VNRX-7145, during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.

BIO-Europe Spring 2019
Monday, March 25 2019 - Wednesday, March 27 2019

Vienna, Austria

BIO CEO & Investor Conference 2019
Monday, February 11 2019 - Tuesday, February 12 2019

New York, NY

Chief Business Officer, Tony Meehan, MBA, PhD, will present attendees with an overview of VenatoRx's pipeline and unique operating model on Monday, February 11, 2019 at 3:30pm ET in the Gramercy room at the New York Marriott Marquis.

J.P. Morgan Health Care Investor Conference 2019
Monday, January 07 2019 - Thursday, January 10 2019

San Francisco, CA

Archive: 2019 | 2018